Hippocratic AI vs Insitro

Insitro has a disclosed valuation of $2.2B, while Hippocratic AI's valuation is not publicly available, making a direct size comparison difficult. Insitro employs 300 people.

Insitro has raised more in total funding at $743M, compared to Hippocratic AI's $120M — a gap of $623M. Combined, the two companies have completed 5 known funding rounds.

Insitro leads with an Awaira Score of 73/100, while Hippocratic AI sits at 65/100. That 8-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Hippocratic AI was founded by Munjal Shah in 2023. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

Hippocratic AI: Hippocratic AI develops a safety-focused AI platform designed to address the global shortage of healthcare professionals by deploying AI agents that perform patient-facing healthcare communication tasks including care navigation, medication adherence outreach, chronic disease monitoring, and post-discharge follow-up. The platform is built around a healthcare-specific large language model with extensive safety evaluation against clinical benchmarks.\n\nThe company raised approximately 120 million USD in early rounds and has established partnerships with health systems and payers focused on reducing care gaps and improving patient engagement at scale. Hippocratic positions its AI as augmenting the healthcare workforce rather than replacing clinicians, targeting the vast volume of lower-acuity patient interactions that do not require physician judgment.\n\nThe healthcare staffing shortage is a structural problem projected to worsen over the next decade, creating durable demand for AI solutions that extend the capacity of existing clinical teams. Hippocratic AI competes with ambient clinical AI companies and general-purpose AI assistant platforms, but its narrow vertical focus on patient-facing healthcare communication and its safety-first design philosophy position it to navigate the regulatory and liability landscape that general AI platforms are less equipped to manage. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, utilizing both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

Insitro got there first, launching in 2018 — that's 5 years of extra runway. Hippocratic AI didn't arrive until 2023. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Hippocratic AI has about 50-200 employees; Insitro has about 300. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Hippocratic AI and Insitro compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.